江中药业(600750) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,227,404,483.82, a decrease of 8.74% compared to ¥1,316,378,726.66 in the same period last year[5] - Net profit attributable to shareholders was ¥266,779,517.36, representing a 9.99% increase from ¥240,831,060.77 year-on-year[5] - The net cash flow from operating activities increased by 10.81% to ¥82,585,412.66, compared to ¥61,891,430.84 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 1,227,404,483.82, a decrease of 8.7% from CNY 1,344,892,149.19 in Q1 2023[45] - The company reported a net profit of CNY 335,215,495.52 for Q1 2024, up 11% from CNY 301,912,707.05 in Q1 2023[45] - The net profit for the current period is 284,545,135.85, an increase from 259,740,521.66 in the previous period, representing a growth of approximately 9.8%[46] - The net profit attributable to shareholders of the parent company is 266,779,517.36, up from 242,556,018.40, indicating a year-over-year increase of about 10%[46] - Basic and diluted earnings per share are both 0.43, compared to 0.39 in the previous period, reflecting an increase of approximately 10.3%[47] - The total comprehensive income for the period is 284,545,135.85, compared to 259,740,521.66 in the previous period, reflecting an increase of about 9.5%[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,527,119,870.40, reflecting a 6.50% increase from the previous year-end[12] - The total assets increased to CNY 6,527,119,870.40 in Q1 2024, compared to CNY 6,128,543,353.58 in Q1 2023, reflecting a growth of 6.5%[36] - The company’s non-current liabilities decreased to CNY 1,525,898,670.79 in Q1 2024 from CNY 1,513,111,560.37 in Q1 2023[36] - The total liabilities amount to 1,766,214,111.28, compared to 1,653,436,913.49 in the previous period, showing an increase of about 6.8%[52] - The total equity attributable to shareholders of the parent company is 4,099,553,812.38, up from 3,831,520,111.84, which is an increase of approximately 7%[52] Cash Flow and Investments - The company's cash and cash equivalents amounted to RMB 1,336,693,596.22, slightly up from RMB 1,332,928,513.42 at the end of 2023, indicating a stable liquidity position[33] - Cash received from sales and services in Q1 2024 was CNY 882,563,080.12, a decrease of 28.2% from CNY 1,230,245,450.50 in Q1 2023[42] - The cash outflow from operating activities in Q1 2024 was CNY 868,702,118.73, down from CNY 1,217,361,823.08 in Q1 2023[42] - Cash and cash equivalents at the end of the period are 656,914,001.03, compared to 492,765,197.35 in the previous period, representing an increase of about 33.3%[49] - The cash flow from investing activities shows a net outflow of -67,261,570.94, an improvement from -132,084,595.20 in the previous period[49] - The company reported cash inflow from investment activities totaling 348,198,778.70, down from 763,792,391.97, indicating a decrease of approximately 54.4%[49] Operational Metrics - The gross profit margin for the pharmaceutical industry segment was 68.89%, an increase of 1.70 percentage points compared to the previous year[16] - Revenue from the non-prescription drug category was ¥1,007,459,807.46, with a year-on-year increase of 4.40%[16] - Revenue from the North China region decreased by 15.28% to ¥234,299,046.19 compared to the same period last year[10] - Total operating costs for Q1 2024 were CNY 899,421,405.12, down 15.3% from CNY 1,061,122,062.19 in Q1 2023[45] - Research and development expenses for Q1 2024 amounted to CNY 28,615,257.33, an increase of 7.4% from CNY 26,642,289.45 in Q1 2023[45] Shareholder Information - The company reported a total of 32,818 common shareholders at the end of the reporting period, with the largest shareholder holding 43.07% of the shares[19] Strategic Initiatives - The company acquired 100% equity of Jiangxi Jiangzhong Changrun Pharmaceutical Co., Ltd. and Jiangxi Jiangzhong Bencao Health Technology Co., Ltd. in November 2023, leading to retrospective adjustments in financial data[7] - The company has engaged in entrusted loans amounting to RMB 13.5 million, with RMB 6.75 million still outstanding and overdue[25] - The company has also invested RMB 50 million in non-principal guaranteed floating wealth management products, with an expected annualized return of 3.68%[29] - The company has initiated legal proceedings to recover overdue loans, with a court ruling in favor of the company's claims against the borrower[25] - The company plans to continue its strategy of expanding its financial investments and managing liquidity effectively in the upcoming quarters[25]